BRAF and melanoma: Although access to systemic treatments expanded during the study period, initially with ipilimumab (2012) [23] and later with targeted therapies such as vemurafenib and cobimetinib for BRAF V600 mutated melanoma (2016) [24], this did not translate into a clear increase in melanoma registrations in SACT.